Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site. by Masini, Tiziana et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Molecular Medicine Articles Department of Molecular Medicine
19-7-2016
Furoates and thenoates inhibit pyruvate
dehydrogenase kinase 2 allosterically by binding to
its pyruvate regulatory site.
Tiziana Masini
University of Groningen
Barbara Birkaya
State University of New York College at Buffalo
Simon van Dijk
University of Groningen
Milon Mondal
University of Groningen
Johan Hekelaar
University of Groningen
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Molecular Medicine at e-publications@RCSI. It has been accepted for
inclusion in Molecular Medicine Articles by an authorized administrator of
e-publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Masini T, Birkaya B, van Dijk S, Mondal M, Hekelaar J, Jäger M, Terwisscha van Scheltinga AC, Patel MS, Hirsch AK, Moman E.
Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site. Journal of
Enzyme Inhibition and Medicinal Chemistry. 2016;19:1-6 .
Authors
Tiziana Masini, Barbara Birkaya, Simon van Dijk, Milon Mondal, Johan Hekelaar, Manuel Jäger, Anke C.
Terwisscha van Scheltinga, Mulchand S. Patel, Anna KH Hirsch, and Edelmiro Moman
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/molmedart/30
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/molmedart/30
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ienz20
Download by: [95.45.121.14] Date: 25 July 2016, At: 07:32
Journal of Enzyme Inhibition and Medicinal Chemistry
ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: http://www.tandfonline.com/loi/ienz20
Furoates and thenoates inhibit pyruvate
dehydrogenase kinase 2 allosterically by binding
to its pyruvate regulatory site
Tiziana Masini, Barbara Birkaya, Simon van Dijk, Milon Mondal, Johan
Hekelaar, Manuel Jäger, Anke C. Terwisscha van Scheltinga, Mulchand S.
Patel, Anna K. H. Hirsch & Edelmiro Moman
To cite this article: Tiziana Masini, Barbara Birkaya, Simon van Dijk, Milon Mondal, Johan
Hekelaar, Manuel Jäger, Anke C. Terwisscha van Scheltinga, Mulchand S. Patel, Anna K. H.
Hirsch & Edelmiro Moman (2016): Furoates and thenoates inhibit pyruvate dehydrogenase
kinase 2 allosterically by binding to its pyruvate regulatory site, Journal of Enzyme Inhibition
and Medicinal Chemistry, DOI: 10.1080/14756366.2016.1201812
To link to this article:  http://dx.doi.org/10.1080/14756366.2016.1201812
View supplementary material Published online: 19 Jul 2016.
Submit your article to this journal Article views: 8
View related articles View Crossmark data
www.tandfonline.com/ienz
ISSN: 1475-6366 (print), 1475-6374 (electronic)
J Enzyme Inhib Med Chem, Early Online: 1–6
! 2016 Informa UK Limited, trading as Taylor & Francis Group. DOI: 10.1080/14756366.2016.1201812
RESEARCH ARTICLE
Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2
allosterically by binding to its pyruvate regulatory site
Tiziana Masini1, Barbara Birkaya2, Simon van Dijk1, Milon Mondal1, Johan Hekelaar3, Manuel Ja¨ger1,
Anke C. Terwisscha van Scheltinga3, Mulchand S. Patel2, Anna K. H. Hirsch1, and Edelmiro Moman4,5
1Stratingh Institute for Chemistry, University of Groningen, Groningen, The Netherlands, 2Department of Biochemistry, School of Medicine and
Biomedical Sciences, University at Buffalo, the State University of New York, Buffalo, NY, USA, 3Groningen Biomolecular Sciences and Biotechnology
Institute, University of Groningen, Groningen, The Netherlands, 4Molecular Design Group, Trinity Biomedical Sciences Institute, Trinity College
Dublin, Dublin, Ireland, and 5RCSI Molecular Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
Abstract
The last decade has witnessed the reawakening of cancer metabolism as a therapeutic target. In
particular, inhibition of pyruvate dehydrogenase kinase (PDK) holds remarkable promise.
Dichloroacetic acid (DCA), currently undergoing clinical trials, is a unique PDK inhibitor in which
it binds to the allosteric pyruvate site of the enzyme. However, the safety of DCA as a drug is
compromised by its neurotoxicity, whereas its usefulness as an investigative tool is limited by
the high concentrations required to exert observable effects in cell culture. Herein, we report
the identification – by making use of saturation-transfer difference NMR spectroscopy,
enzymatic assays and computational methods – of furoate and thenoate derivatives as
allosteric pyruvate-site-binding PDK2 inhibitors. This work substantiates the pyruvate regula-
tory pocket as a druggable target.
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Introduction
Metabolic reprogramming is essential for the viability of cells
trapped in a pathological state of constitutive growth and
proliferation1. New findings are shedding light on the mechanisms
orchestrating such reprogramming and favour a comprehensive
paradigm that recognizes an altered metabolism as a core
hallmark of cancer2,3. The signalling and metabolic pathways
implicated in cancer bioenergetics are thus (re)emerging as
promising therapeutic targets4.
Cancer cells tend, for instance, to divert glucose towards
cytosolic lactic acid production, a phenomenon historically
referred to as the Warburg effect5. In turn, inhibitors of protein
dehydrogenase kinase (PDK), whose isoforms 1 and 3 are
upregulated in several cancers6, have been shown to reverse this
phenomenon, hence hampering tumours from meeting their
abnormal metabolic requirements7.
PDK is a tightly regulated mitochondrial kinase that inhibits
the activity of the pyruvate dehydrogenase complex (PDC) via
reversible phosphorylation8. Several allosteric sites have been
identified in its regulatory domain, including the pyruvate-
binding pocket, which induces the inactivation of the enzyme as
pyruvate concentration raises9. Synthetic PDK inhibitors have
been discovered for all four binding sites that are large enough to
host small organic molecules10–16. However, dichloroacetic acid
(DCA) remained to date the only bona fide pyruvate-site PDK
synthetic inhibitor10–12.
DCA has already shown significant promise in vivo8, either
alone or in combination therapy17. However, the limited clinical
studies conducted so far remain insufficient to appraise the
therapeutic value of the compound18. Moreover, several reports
caution about its potential neurotoxic side effects19. The useful-
ness of DCA as an investigative chemical probe for the study of
cancer metabolism is also limited as a consequence of the high
concentrations (ranging from 17 to 50 mM) required in order to
observe a significant effect in cell culture20.
The aim of this study was to determine whether or not the
pyruvate regulatory site of PDK is a druggable pocket with a view
to develop novel inhibitors with improved therapeutic profiles as
compared to DCA. Advantages of targeting the pyruvate
pocket include the fact that it is a well-defined and largely
hydrophobic pocket10 and that inhibitors binding to this site are
noncompetitive7.
Materials and methods
Starting materials and reagents were purchased from Aldrich,
Acros, Alfa Aesar or Apollo Scientific. All solvents were reagent-
grade and, if necessary, dried and distilled prior to use. All
reactions were run under a nitrogen atmosphere unless otherwise
stated. Column chromatography was performed using silica gel
(Silicycle SiliaSepTM 40–63mm). TLC was performed with
silica gel 60/Kieselguhr F254. 1H-NMR and 13C-NMR spectra
were recorded at 400 MHz on a Varian AMX400 spectrometer
(400 MHz for 1H, 101 Hz for 13C) at 25 C. Chemical shifts () are
Address for correspondence: Edelmiro Moman, Molecular Design Group,
Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2,
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reported relative to the residual solvent peak (CD3OD, 1H¼ 3.31;
13C¼ 49.15. (CD3)2SO, 1H¼ 2.50; 13C¼ 39.52). Splitting pat-
terns are indicated as (s) singlet and (d) doublet. High-resolution
mass spectra were recorded with an LTQ Orbitrap XL (Thermo
Fisher Scientific) mass spectrometer, using ESI as ionization
source. FT-IR were measured on PerkinElmer FT-IR spectrom-
eter. Melting points (mp) were measured with a Buchi melting
point B-545. Some of the compounds were purchased from Sigma
(2), Maybridge (4), Apollo (5, 12, 16), Acros (6, 13, 14), and Alfa
Aesar (15) and used without further purification after confirming
their identity and purity by 1H-NMR. Compounds 721, 322, 1723
were prepared according to literature procedures and their spectral
data are consistent with the literature. Proof of purity was
obtained for all compounds subjected to biochemical assays
(495% purity by HPLC).
Experimental
Model building
In order to fill the missing regions in the template, a model of
human PDK2 was built with Modeller 9v2 using the crystal
structure 2BU810 as a template. ADP, DCA, Mg+2 and the
coordinated water molecules were kept from the template,
whereas a K+ ion bound to the potassium binding site and one
coordinated water molecule were added from 3CRK. The added
loops were refined with Modeller. The resulting model, solvated
within a water box 14 A˚ larger than the molecular system
dimensions and neutralized with 0.15 M KCl, was relaxed using
NAMD by means of an alternate series of energy minimizations
and molecular dynamics simulations using periodic boundary
conditions (PBC) and the canonical ensemble. First, only the bulk
solvent and ions were allowed to relax, next, different parts of the
system were consecutively freed in the following order: hydrogen
atoms, loops, side chains and, finally, the entire system was
relaxed. Initial CHARMM general force field parameters for DCA
were derived using the SwissParam server and the initial topology
was refined on the basis of PCM/MP2/6-31 + g(d,p) calculations
carried out with GAMESS24. The quality of the final and
intermediate protein models was evaluated with MolProbity.
Calculation of binding enthalpies
The geometry of all the described ligands was optimized at the
PCM/MP2/6-31 + g(d,p) level of theory with GAMESS24.
The compounds were docked using AutoDock Vina25 into the
pyruvate site of the protein structure model built from 2BU810 as
described previously. The enthalpies of binding were reevaluated
for each complex at the COSMO/PM6-DH+//COSMO/PM6-
DH2X level of theory (the full complexes were minimized with
PM6-DH+26 and single-point calculations on the minimized
structures were then carried out with PM6-DH2X27) using
MOPAC201228. Two alternative poses for each ligand were
evaluated. The data reported correspond to that with the most
favourable PM6-DH2X binding energy.
Ligand efficiency
Solvent accessible surface areas (ASAs) were computed with
ASV29 taking the van der Waals radii from Mantina et al.30
Overexpression and purification of PDC proteins
Recombinant human E1 mutant (the a subunit with only
phosphorylation site 1 functional and the serine residues at sites
2 and 3 replaced with alanine31) and wild-type human E332 were
overexpressed in E. coli BL21 cells, purified using Ni2+-NTA-
agarose chromatography and eluted with a linear 50–200 mM
imidazole gradient. The resulting proteins were 95% pure as
judged by SDS-PAGE densitometry. Recombinant human E2-
E3BP was co-expressed and purified from BL21 cells harbouring
pP-DHE2/E3BP as described by Yang et al.33 with minor
modifications34. Human PDK2 was amplified from cDNA made
from HEK293 cells and subcloned into pET-28b. Recombinant
human PDK2 was purified from BL21 cells transformed with
pET-28b expression vector as described previously34,35.
PDC activity assay
PDK inhibitors were dissolved in DMSO to the concentration of
100 mM. Subsequent dilutions were done with double distilled
water. DMSO had no effect on PDC activity. All the inhibitors
were investigated for their ability to alter the PDC activity. None
of the inhibitors affected PDC activity when used alone or in the
presence of PDK2 (without added ATP). The PDC assay took the
advantage of PDK-dependent phosphorylation of the a subunit of
E1 resulting in the inhibition of PDC activity. Phosphorylation of
mutant E1 (the a subunit with only phosphorylation site 1
functional and the serine residues at sites 2 and 3 replaced with
alanine) was measured by inactivation of PDC by PDK231. Since
there was only one functional phosphorylation site (site 1) in the
mutant E1, the rate of its phosphorylation correlated with the rate
of PDC inactivation. In the two-step assay, the PDK assay was
conducted first with the known PDC activity in the presence of
PDK2 causing phosphorylation and hence inactivation of PDC. In
the second step, the remaining PDC activity is measured using
PDC assay31. PDC proteins with final concentrations of: 0.1 mg/
mL E1, 0.1 mg/ml E2-E3BP, 0.05 mg/mL dihydrolopoamide
dehydrogenase component (E3) and 0.15 mg/mL PDK2 were
incubated in a premix (20 mM KHPO4, pH 7.5, 1 mM MgCl2,
0.05 mM EDTA, 1 mM dithiothreitol) for 10 min at 4 C to allow
formation of the PDC complex. Aliquots (10 mL) were taken and
3mL of 0.25 mM ATP was added to start PDK2 reaction, and after
2 min 10 mL was transferred to PDC assay mixture. PDC activity
was measured in 1 mL reaction mixture (50 mM potassium
phosphate, pH 7.5, 2 mM MgCl2, 1.4 mM NAD
+, 500 mM
thiaminpyrophosphate, 4 mM cysteine and 156mM coenzyme
A). The reaction was started by the addition of pyruvate to a final
concentration of 2 mM and the change in absorbance at 340 nm/
min was measured to calculate PDC activity34.
Dynamic light scattering
Dynamic light scattering (DynaPro NanoStar; Wyatt) was used to
characterize the purified protein sample. The sample (5 mg/mL)
was centrifuged for 5 min at 14 000g. The analyses showed two
molecular weight populations (two peaks). One, 98% of the mass,
represents the PDK2 dimer with a polydispersity of 40% based
on the mass. The second peak, 2% of the mass represents a
much larger complex with very high polydispersity such as
protein aggregate. Storage for several days on ice in the cold room
showed comparable DLS results, indicating that the purified
protein sample is stable under these conditions.
STD-NMR binding experiments
All 1H-STD-NMR experiments were performed at 10 C on a
Varian 600 MHz spectrometer. The on-resonance irradiation on
PDK2 was set at –1 ppm. In each experiment, one ligand and
PDK2 were present. The final concentrations of ligand and PDK2
were 400mm and 10 mm, respectively, ([PDK2]:[ligand]¼ 1:40).
First, the 1H-NMR spectra of ligands in HEPES buffer (20 mM
HEPES of pH 8, 100 mM KCl, 10 mM b-mercaptoethanol
and 0.1 M EDTA in deuterated water), in presence of pro-
tein (off-resonance 1H NMR spectra) were recorded.
2 T. Masini et al. J Enzyme Inhib Med Chem, Early Online: 1–6
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Subsequently, on-resonance 1H-NMR spectra were recorded with
1000 scans. 1H-STD-NMR spectra were obtained by subtracting
the on-resonance spectrum from the corresponding off-resonance
spectrum (Figures S5–S10). 1H-STD-NMR analysis revealed that
all six ligands bind to the protein.
1H-STD-NMR competition experiments
To confirm that all the ligands bind to the same pocket of PDK2
as DCA, a competition experiment was performed using 8 (which
has the highest activity from all ligands investigated). First, the
1H-STD-NMR of 400mM 8 was recorded as mentioned above.
Subsequently, 400mM DCA was added to the same NMR tube and
a second 1H-STD NMR spectrum was recorded. The second 1H-
STD-NMR spectrum showed the appearance of DCA peaks and
disappearance of peaks from 8, which indicated that 8 was
displaced by DCA from the binding pocket of PDK2 (Figure S11).
This experiment confirms that both 8 and DCA bind to the same
binding pocket of the enzyme.
Results and discussion
By making use of structure-based design and virtual screening
techniques, we have identified a number of chemical scaffolds as
potential inhibitors of PDK targeting the pyruvate-binding site.
Herein, we report our first enzymatic activity results with furoate
and thenoate derivatives. Figure 1 displays the structures of the
compounds, which were either synthesized or purchased and
subjected to biochemical evaluation.
The rationale for privileging such scaffolds at the proof-of-
concept phase is two-fold: On the one hand, their structures
resemble that of pyruvate but are more versatile in terms of
derivatisation; and, on the other hand, furoates are known
to be intermediates in the energy metabolism of certain
microorganisms36.
Furthermore, in terms of molecular recognition, molecular
docking calculations predict furoates and thenoates to bind to the
pyruvate site of PDK2 in a pose resembling that observed for
DCA in the crystal structure with PDBID 2BU810. Figure 2 shows
the binding mode of DCA (2) within the pyruvate-binding site of
PDK2. The predicted binding pose for the most active compound
of the series, 8, is also displayed (balls and sticks). A carboxylate
or other negatively charged functional group seems to be
fundamental for the initial recognition by gate residues Arg154
and Arg158 (human PDK2 numbering is used, unless otherwise
stated), in addition to establishing a hydrogen bond/salt bridge
network with Tyr80, Arg154 and, potentially, Arg158. In turn, the
aromatic moiety is predicted to establish a –-stacking inter-
action with the side chain of His115. Furthermore, the methyl
substituent allows this compound to maintain additional van der
Waals interactions with Leu49 and Ile87.
The inhibitory activity of the reported compounds was
determined indirectly by means of the PDC assay31. PDC activity
is regulated by phosphorylation/dephosphorylation of the a
subunit of the pyruvate dehydrogenase component (E1) on three
specific serine residues: SER264 (site 1), SER271 (site2) and
SER203 (site 2). PDK2 inhibits PDC by phosphorylating sites 1
and 2, but not 334. In order to observe a more linear effect
between E1a phosphorylation and PDC inactivation, and provided
that PDK2 presents the highest affinity towards site 1, sites 2 and
3 were mutated to alanine31.
PDC activity was evaluated, respectively, in the absence of
both PDK2 and the inhibitors; in the presence of each of the
inhibitors but without PDK2 (this permitted us to exclude a direct
effect of our compounds on PDC activity); in the presence of
fully-active PDK2 with no inhibitor; and, finally, in the presence
of both PDK2 and each of the inhibitors at concentrations ranging
from 1mM to 1 mM. The results are summarized in Table 1 and
represent the percentage of restoration of PDC activity in the
presence of the inhibitor, thus [100 (APDC + PDK2 + Inhibitor –
APDC + PDK2)/(APDC – APDC + PDK2)], where APDC is the activity
of PDC alone, APDC + PDK2 is the activity of PDC in the presence
of PDK2, and APDC + PDK2 + Inhibitor is the activity of PDC in the
presence of both PDK2 and the respective inhibitor at a given
concentration.
As it can be seen in Table 1, DCA (2) is the most active
compound, being able to restore, through PDK2 inhibition, 50%
of PDC activity at 0.01 mM and 100% at 0.1 mM. Our most active
compound in these series is thenoate 8, which restored 75% of
PDC activity at 0.1 mM. In turn, compounds 4, 11, 12 and 15 were
able to restore 50% of the basal activity at 0.1 mM and 100% at
1 mM. Finally, compound 5 restored complete PDC activity at
1 mM but showed no inhibitory activity at lower concentrations.
None of the thenoates and furoates showed any sizeable inhibitory
activity at 0.01 mM.
1H Saturation-transfer difference NMR (1H-STD-NMR)
experiments confirmed that 2, 4, 5, 8, 11 and 12 bind directly
to PDK2. In addition, we employed 1H-STD-NMR spectroscopy
to carry out competition assays between DCA (2) and 8, which
revealed that DCA displaces 8 from the binding site of the
enzyme. This experiment demonstrated that both DCA and 8 bind
to the same pocket of the enzyme. Given that DCA is a bona fide
pyruvate-site inhibitor10–12, we conclude that, as predicted by the
computational studies, 8 exerts its inhibitory action by binding to
the allosteric pyruvate regulatory site of the enzyme.
In terms of structure–activity relationships (SARs), it is
noteworthy that four (4, 11, 12 and 15) out of the five most
Figure 1. Structures of pyruvic acid (1) and the tested compounds.
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potent compounds bear either a methyl or a bromo substituent in
ortho position with respect to the carboxylate moiety and that 5,
the only tested compounds with no substituents, was active only at
higher concentrations. Comparing the activities of 3 and 4, we
observed that while the 2-bromo derivative 4 is active, the 2-
chloro derivative 3 is not. However, the thenoate 6 bearing the
same substitution pattern as furoate 4 is essentially inactive.
Instead, both 4-bromo (12) and 4-methyl (11) substitutions are
beneficial, as it is 5-methyl (8). The presence of either a bromine
or a chlorine atom at the 5th-position of the series of thenoates
(compounds 10 and 9, respectively) causes complete loss of
activity. As for the 2-thenoate series, the most active compound,
15, has a methyl group ortho to the carboxylate moiety, whereas
16, with a hydroxyl group at the same position, is less active.
In order to evaluate the enthalpy of binding (DHB) for each
protein–ligand complex, the missing regions where added to
2BU8 by homology modelling and then the structure was relaxed
through a series of energy minimization and molecular dynamics
simulations cycles. Each protein–ligand complex was then
minimized with different semi-empirical parameterization
models, both with the COSMO solvent model and in the gas
phase. The enthalpy of binding was computed as
[DHB¼DHC (DHP+DHL)], where DHB is the enthalpy of
binding, DHC the heat of formation of the protein–ligand
complex, DHP the heat of formation of the protein and DHL the
heat of formation of the ligand. Ligand efficiency37 was then
calculated with the formula [–DHB (ASAC/ASAL)], where DHB
is the computed enthalpy of binding, ASAC is the solvent-ASA of
Figure 2. Predicted binding mode of com-
pound 8 (balls and sticks) superimposed with
the PDK2/DCA co-crystal structure 2BU8
(sticks).
Table 1. Percentage restoration of PDC activity at different concentrations of PDK inhibitors with respect to fully active
PDK2. Enthalpies of binding computed at the PM6-DHX2 level of theory. Ligand efficiency.
Restoration of PDC activity (%)
–DHB (kcal/mol)
1 mM 0.1 mM 0.01 mM 0.001 mM PM6-DHX2 Ligand efficiency
1 – – – – 8.72 1.30
2 107 ± 2 119 ± 4 55 ± 9 15 ± 8 36.61 4.96
3 25 ± 12 12 ± 8 5 ± 8 – 40.80 4.57
4 93 ± 12 54 ± 8 26 ± 9 – 39.95 4.34
5 108 ± 9 36 ± 8 16 ± 8 – 27.98 3.35
6 37 ± 7 12 ± 15 5 ± 18 – 23.58 2.41
7 76 ± 1 33 ± 6 12 ± 9 – 10.60 0.95
8 129 ± 8 75 ± 8 16 ± 10 – 25.67 2.66
9 38 ± 11 4 ± 16 – – 28.88 3.03
10 33 ± 8 5 ± 8 – – 17.44 1.78
11 141 ± 8 47 ± 8 17 ± 8 – 37.31 3.85
12 103 ± 8 45 ± 8 16 ± 11 – 24.58 2.52
13 91 ± 1 29 ± 5 9 ± 5 – 25.80 2.67
14 40 ± 9 7 ± 9 8 ± 14 – 26.13 2.71
15 99 ± 8 47 ± 8 12 ± 9 – 33.46 3.52
16 75 ± 8 38 ± 9 4 ± 4 – 29.97 3.33
17 5 ± 9 – – – 29.43 2.53
4 T. Masini et al. J Enzyme Inhib Med Chem, Early Online: 1–6
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the carbon atom and ASAL is that of the ligand. This is
approximately equivalent to the enthalpy of binding per atom
adjusted to take atom size into account. Enthalpies of binding and
ligand efficiency data are summarized in Table 1.
Figure 3 shows the correlation between enzymatic activity and
ligand efficiency computed at the COSMO/PM6-DH2X level of
theory. It must be noted that the chosen methodology has a
number of limitations, which include neglecting the entropic term
of the free energy of binding and the inaccurate estimation of the
van der Waals interactions with semi-empirical methods.
It is, however, noteworthy that both COSMO/PM6-DH + and
COSMO/PM6-DH2X correctly predict that DCA is the most
efficient ligand. Moreover, the higher level of theory employed,
the better the statistical correlation between enzymatic activity
and computed ligand efficiency we observe in relative terms.
Thus, using the conductor-like screening model COSMO with the
dielectric constant of water produced better results in all cases,
except PM7, than the corresponding calculations at the homolo-
gous level of theory in the gas phase. As for the parameterisation
model, plain PM6 and PM7 gave the worst results. Including
hydrogen-bond corrections at the PM6-DH + level of theory
further improved the statistical correlation, whereas the best
results were obtained when both hydrogen bond and halogen bond
corrections as implemented in PM6-DH2X were used. Taken
together, these results indicate that the predicted binding mode is
correct for a significant number of the tested compounds.
Conclusion
Through enzymatic PDC activity assays we have identified
several compounds bearing either furoate or thenoate scaffolds as
PDK2 inhibitors. 1H-STD-NMR experiments with the five most
potent compounds and DCA demonstrated that they bind directly
to PDK2. Competition experiments also demonstrated that the
most potent compound competes with DCA for PDK2 binding.
Taken together, these data indicate that, as predicted theoretically,
the reported compounds inhibit PDK2 allosterically via binding to
its pyruvate-binding site, thus substantiating this small regulatory
site as a druggable target and paving the way towards the design
of novel inhibitors with improved pharmacological profiles.
Declaration of interest
The authors declare no competing financial interest. This work
has received funding from the National Institutes of Health
(M.S.P.) the Netherlands Organization for Scientific Research
(A.K.H.H.) and the Dutch Ministry of Education, Culture and
Science (A.K.H.H.). The National Institutes of Health (NIH) is
acknowledged for Grant DK20478 to M.S.P. The Netherlands
Organization for Scientific Research is acknowledged for Grant
NWO-CW, ECHO-STIP to A.K.H.H. The Dutch Ministry of
Education, Culture and Science for Gravitation Program Grant
024.001.035 to A.K.H.H.
References
1. Schulze A, Harris AL. How cancer metabolism is tuned for
proliferation and vulnerable to disruption. Nature 2012;491:364–73.
2. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell
metabolism. Nat Rev Cancer 2011;11:85–95.
3. Ward PS, Thompson CB. Metabolic reprogramming: a cancer
hallmark even Warburg did not anticipate. Cancer Cell 2012;21:
297–308.
4. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for
cancer therapy. Nat Chem Biol 2015;11:9–15.
5. Kim J, Dang CV. Cancer’s molecular sweet tooth and the Warburg
effect. Cancer Res 2006;66:8927–30.
6. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated
expression of pyruvate dehydrogenase kinase: a metabolic switch
required for cellular adaptation to hypoxia. Cell Metab 2006;3:
177–85.
7. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-
K + channel axis is suppressed in cancer and its normalization
promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;
11:37–51.
8. Patel MS, Nemeria NS, Furey W, Jordan F. The pyruvate
dehydrogenase complexes: structure-based function and regulation.
J Biol Chem 2014;289:16615–23.
Figure 3. Correlation between percent restor-
ation of PDC activity at 0.1 mM (x-axis) and
computed ligand efficiency (y-axis).
DOI: 10.1080/14756366.2016.1201812 Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically 5
D
ow
nl
oa
de
d 
by
 [9
5.4
5.1
21
.14
] a
t 0
7:3
2 2
5 J
uly
 20
16
 
9. Roche TE, Hiromasa Y. Pyruvate dehydrogenase kinase regulatory
mechanisms and inhibition in treating diabetes, heart ischemia, and
cancer. Cell Mol Life Sci 2007;64:830–49.
10. Knoechel TR, Tucker AD, Robinson CM, et al. Regulatory roles of
the N-terminal domain based on crystal structures of human
pyruvate dehydrogenase kinase 2 containing physiological and
synthetic ligands. Biochemistry 2006;45:402–15.
11. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechan-
isms for inhibition of pyruvate dehydrogenase kinase isoforms by
AZD7545, dichloroacetate, and radicicol. Structure 2007;15:
992–1004.
12. Li J, Kato M, Chuang DT. Pivotal role of the C-terminal DW-motif
in mediating inhibition of pyruvate dehydrogenase kinase 2 by
dichloroacetate. J Biol Chem 2009;284:34458–67.
13. Kukimoto-Niino M, Tokmakov A, Terada T, et al. Inhibitor-bound
structures of human pyruvate dehydrogenase kinase 4. Acta
Crystallogr D Biol Crystallogr 2011;67:763–73.
14. Tso S-C, Qi X, Gui W-J, et al. Structure-guided development of
specific pyruvate dehydrogenase kinase inhibitors targeting the
ATP-binding pocket. J Biol Chem 2014;289:4432–43.
15. Moore JD, Staniszewska A, Shaw T, et al. VER-246608, a novel
pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase
kinase, disrupts Warburg metabolism and induces context-dependent
cytostasis in cancer cells. Oncotarget 2014;5:12862–76.
16. Mann WR, Dragland CJ, Vinluan CC, et al. Diverse mechanisms of
inhibition of pyruvate dehydrogenase kinase by structurally distinct
inhibitors. Biochim Biophys Acta 2000;1480:283–92.
17. Xie Q, Zhang H-F, Guo Y-Z, et al. Combination of Taxol and
dichloroacetate results in synergistically inhibitory effects on Taxol-
resistant oral cancer cells under hypoxia. Mol Med Rep 2015;11:
2935–40.
18. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic
modulation of glioblastoma with dichloroacetate. Sci Transl Med
2010;2:31–4.
19. Brandsma D, Dorlo TPC, Haanen JH, et al. Severe encephalopathy
and polyneuropathy induced by dichloroacetate. J Neurol 2010;257:
2099–100.
20. Stockwin LH, Yu SX, Borgel S, et al. Sodium dichloroacetate
selectively targets cells with defects in the mitochondrial ETC. Int J
Cancer 2010;127:2510–19.
21. Pomerantz M, Yang H, Cheng Y. Poly(alkyl thiophene-3-carboxyl-
ates). Synthesis and characterization of polythiophenes with a
carbonyl group directly attached to the ring. Macromolecules 1995;
28:5706–8.
22. Schnute ME, Brideau RJ, Collier SA, et al. Synthesis of 4-oxo-4,7-
dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum
human herpesvirus polymerase inhibition. Bioorg Med Chem Lett
2008;18:3856.
23. Obrecht D, Ermert P, Oumouch S, et al. Conformationally
constrained, fully synthetic macrocyclic compounds. International
Patent Application WO/2011/014973, 2011; Polyphor AG.
24. Schmidt MW, Baldridge KK, Boatz JA, et al. General atomic and
molecular electronic structure system. J Comput Chem 1993;14:
1347–63.
25. Trott O, Olson AJ. AutoDock Vina: improving the speed and
accuracy of docking with a new scoring function, efficient
optimization and multithreading. J Comput Chem 2010;31:455–61.
26. Korth M. Third-generation hydrogen-bonding corrections for
semiempirical QM methods and force fields. J Chem Theory
Comput 2010;6:3808–16.
27. Dobesˇ P, Rˇeza´cˇ J, Fanfrlı´k J, et al. Semiempirical quantum
mechanical method PM6-DH2X describes the geometry and ener-
getics of CK2-inhibitor complexes involving halogen bonds well,
while the empirical potential fails. J Phys Chem B 2011;115:8581–9.
28. Stewart JJP. MOPAC2012 [Internet]. Colorado Springs, CO, USA:
Stewart Computational Chemistry; 2012. Available from: http://
OpenMOPAC.net.
29. Petitjean M. On the analytical calculation of van der Waals surfaces
and volumes: some numerical aspects. J Comput Chem 1994;15:
507–23.
30. Mantina M, Chamberlin AC, Valero R, et al. Consistent van der
Waals radii for the whole main group. J Phys Chem A 2009;113:
5806–12.
31. Korotchkina LG, Patel MS. Mutagenesis studies of the phosphor-
ylation sites of recombinant human pyruvate dehydrogenase. Site-
specific regulation. J Biol Chem 1995;270:14297–304.
32. Liu TC, Korotchkina LG, Hyatt SL, et al. Spectroscopic studies of
the characterization of recombinant human dihydrolipoamide
dehydrogenase and its site-directed mutants. J Biol Chem 1995;
270:15545–50.
33. Yang D, Song J, Wagenknecht T, Roche TE. Assembly and full
functionality of recombinantly expressed dihydrolipoyl acetyltrans-
ferase component of the human pyruvate dehydrogenase complex.
J Biol Chem 1997;272:6361–9.
34. Korotchkina LG, Patel MS. Probing the mechanism of inactivation
of human pyruvate dehydrogenase by phosphorylation of three sites.
J Biol Chem 2001;276:5731–8.
35. Bowker-Kinley MM, Davis WI, Wu P, et al. Evidence for existence
of tissue-specific regulation of the mammalian pyruvate dehydro-
genase complex. Biochem J 1998;329:191–6.
36. Wierckx N, Koopman F, Ruijssenaars HJ, de Winde JH. Microbial
degradation of furanic compounds: biochemistry, genetics, and
impact. Appl Microbiol Biotechnol 2011;92:1095–105.
37. Hopkins AL, Keseru¨ GM, Leeson PD, et al. The role of ligand
efficiency metrics in drug discovery. Nat Rev Drug Discov 2014;13:
105–21.
Supplementary material available online
6 T. Masini et al. J Enzyme Inhib Med Chem, Early Online: 1–6
D
ow
nl
oa
de
d 
by
 [9
5.4
5.1
21
.14
] a
t 0
7:3
2 2
5 J
uly
 20
16
 
